Reacción a "A patient has been in remission from cancer for 18 years after CAR-T treatment as a child, the longest period ever described"

This is a study documenting the case of a pediatric patient with neuroblastoma who was treated in the context of a phase 1 clinical trial with autologous T lymphocytes expressing first-generation chimeric antigen receptors (CARs) (CARs without co-stimulus domains) against GD2, and who has been in remission for more than 18 years. 

These data demonstrate the safety of the strategy and suggest that CAR-T cells could provide long-term benefits in patients with some types of solid tumors. 

It provides biological information on the behavior of CAR cells that could be useful in designing future studies. This is the first study to compare the efficacy and persistence of CAR-T cells generated from T lymphocytes expanded with anti-CD3 antibodies and those generated from Epstein-Barr virus-specific lymphocytes using genetic techniques. In addition, the repertoire of specific receptors (TCR) in the above-mentioned subpopulations is studied. 

This is a small series with a single patient and an observational period of 18 years. To validate these findings and the potential therapeutic impact of new generation CAR-T therapies in patients with neuroblastoma and other types of solid tumors, larger series are essential.